Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Serotonin Syndrome 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Dumping Syndrome 1Congenital Hyperinsulinism 1Carcinoma, Neuroendocrine 1Carcinoma 1Adrenocortical Hyperfunction 1Adenoma, Islet Cell 1ACTH Syndrome, Ectopic 1

Interventions

fluorodopa F 18 3pasireotide 1Solutions 1Saline Solution 1Injections 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperinsulinism × pasireotide × Endocrine × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡